Nexo Therapeutics, Inc.
Last verified 2026-06-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $60.0Mattributed |
|---|---|
| Latest round | Funding round, $60.0M, 2026-03-27attributed |
| Founded | unknown |
| Headquarters | LITTLETON, CO |
| Industry | biotechnology |
| Stage | unknown |
| Website | nexotx.com |
Nexo Therapeutics is a drug-discovery company developing covalent medicines aimed at proteins long considered undruggable. It targets diseases driven by transcription factors, scaffolding proteins, and other targets traditional drugs cannot reach. Its covalent ligand discovery platform spans all nucleophilic amino acids and captures shallow, transient pockets that conventional approaches miss.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-03-27 | Funding round | $60.0M | undisclosed |
Detected tech stack
bootstrap, carto analytics, cloudflare, http/3, jquery 3.7.1, jquery migrate 3.4.1, mysql, php 8.4.21, underscore.js, understrap, wordpress 7.0
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $60.0M | attributed | sec-edgar named as publisher. No document URL on file. |
| Total raised $60.0M | attributed | sec-edgar named as publisher. No document URL on file. |
| Company existence | self-reported | nexotx.com, read 2026-06-07 |
| Description | self-reported | nexotx.com, read 2026-06-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $60.0M, 2026-03-27 → Funding round, $60.0M, 2026-03-27, sec-edgar, No document URL on file | Latest round | seed, $60.0M, 2026-03-27 → Funding round, $60.0M, 2026-03-27 | sec-edgar, No document URL on file |
Records begin 2026-09-24. All changes